Dyne Therapeutics to Participate in Upcoming Investor Conferences

About this update from Dyne Therapeutics, Inc.

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at  https://investors.dyne-tx.com/news-and-events/events-and-presentations  and a replay will be accessible for 90 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more  https://www.dyne-tx.com/ , and follow us on  X , LinkedIn  and Facebook . Contacts: Investors Mia Tobias [email protected] 781-317-0353 Media Stacy Nartker  [email protected] 781-317-1938

View stock analysis, news, and events for Dyne Therapeutics, Inc.